✦ LIBER ✦

Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial

✍ Scribed by Alexander MM Eggermont; Stefan Suciu; Mario Santinami; Alessandro Testori; Wim HJ Kruit; Jeremy Marsden; Cornelis JA Punt; François Salès; Martin Gore; Rona MacKie; Zvonko Kusic; Reinhard Dummer; Axel Hauschild; Elena Musat; Alain Spatz; Ulrich Keilholz

Book ID: 117303259
Publisher: The Lancet
Year: 2008
Tongue: English
Weight: 236 KB
Volume: 372
Category: Article
ISSN: 0140-6736
DOI: 10.1016/s0140-6736(08)61033-8

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Serum concentrations of pegylated interf

Serum concentrations of pegylated interferon α-2b in patients with resected stage III melanoma receiving adjuvant pegylated interferon α-2b in a randomized phase III trial (EORTC 18991)

✍ Alexander M. M. Eggermont; Marna G. Bouwhuis; Wim H. Kruit; Alessandro Testori; 📂 Article 📅 2009 🏛 Springer 🌐 English ⚖ 341 KB

Post-surgery adjuvant therapy with inter

Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial

✍ Alexander MM Eggermont; Stefan Suciu; Rona MacKie; Wlodzimierz Ruka; Alessandro 📂 Article 📅 2005 🏛 The Lancet 🌐 English ⚖ 126 KB

5LB Prognostic value of autoantibodies i

5LB Prognostic value of autoantibodies in melanoma stage III patients in the EORTC 18991 phase III randomized trial comparing adjuvant pegylated interferon α2b vs observation

✍ M.G. Bouwhuis; S. Suciu; A. Testori; M. Santinami; W.H. Kruit; C.J. Punt; F. Sal 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 41 KB

Tolerability of intensified intravenous

Tolerability of intensified intravenous interferon alfa-2b versus the ECOG 1684 schedule as adjuvant therapy for stage III melanoma: a randomized phase III Italian Melanoma Inter-group trial (IMI – Mel.A.) [ISRCTN75125874]

✍ Vanna Chiarion-Sileni; Paola Del Bianco; Antonella Romanini; Michele Guida; Adri 📂 Article 📅 2006 🏛 BioMed Central 🌐 English ⚖ 407 KB

Final results of the EORTC 18871/DKG 80-

Final results of the EORTC 18871/DKG 80-1 randomised phase III trial: rIFN-α2b versus rIFN-γ versus ISCADOR M® versus observation after surgery in melanoma patients with either high-risk primary (thickness >3 mm) or regional lymph node metastasis

✍ U.R. Kleeberg; S. Suciu; E.B. Bröcker; D.J. Ruiter; C. Chartier; D. Liénard; J. 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 292 KB